Similar Search Results

Cost Comparison of Antibacterial Therapies for Serious Infections: A New Zealand 3-Hospital Study

Scott, W. Guy; Scott, Helen M.; Henderson, Seton; … - In: PharmacoEconomics 16 (1999) 2, pp. 183-192

360 patient-treatment days and 8 antibacterials. Main outcome measures and results: Drug acquisition cost ranged from 4 …

Persistent link: https://www.econbiz.de/10005590387

Cost Analysis of an Adult Outpatient Parenteral Antibiotic Therapy (OPAT) Programme: A Canadian Teaching Hospital and Ministry of Health Perspective

Wai, Amy O.; Frighetto, Luciana; Marra, Carlo A.; Chan, … - In: PharmacoEconomics 18 (2000) 5, pp. 451-457

Background: Outpatient parenteral antibiotic therapy (OPAT) programmes have become prevalent over the past 2 decades. From the US perspective, these programmes have been shown to reduce healthcare costs. No comprehensive analysis has been published from the Canadian perspective. Objective: To...

Persistent link: https://www.econbiz.de/10005590540

Cost Effectiveness of Cephalosporin Monotherapy and Aminoglycoside/ Ureidopenicillin Combination Therapy: For the Treatment of Febrile Episodes in Neutropenic Patients

Paladino, Joseph A.; Fong, Debra A.; Forrest, Alan; … - In: PharmacoEconomics 18 (2000) 4, pp. 369-381

utilisation included costs for study antibacterials, treatment of adverse effects and failures, and hospitalisation. The primary …

Persistent link: https://www.econbiz.de/10005590555

Erratum

Adis International Limited - In: PharmacoEconomics 30 (2012) 1, pp. 81-81

Persistent link: https://www.econbiz.de/10009421259

A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis

Fitzpatrick, Christopher; Floyd, Katherine - In: PharmacoEconomics 30 (2012) 1, pp. 63-80

Background: Around 0.4 million cases of multidrug-resistant tuberculosis (MDR-TB) occur each year. Only a small fraction of these cases are treated according to international guidelines. Evidence relevant to decisions about whether to scale-up treatment for MDR-TB includes cost and...

Persistent link: https://www.econbiz.de/10010614379

Health Economic and Infectious Disease Modelling: A Guide to Merging Streams

Anonychuk, Andrea; Krahn, Murray - In: PharmacoEconomics 29 (2011) 5, pp. 367-369

Persistent link: https://www.econbiz.de/10010614410

Acute Rhinosinusitis: A Pharmacoeconomic Review of Antibacterial Use

Wasserfallen, Jean-Blaise; Livio, Francoise; Zanetti, … - In: PharmacoEconomics 22 (2004) 13, pp. 829-837

a viral infection with or without bacterial superinfection. Although spontaneous resolution is common, antibacterials … have compared antibacterials with placebo and few have suggested that antibacterials are superior to placebo, except when a … trials were published between 1989 and 2002, that compared the relative efficacy of various antibacterials. Most of these …

Persistent link: https://www.econbiz.de/10005449063

Management and Prevention of Diabetic Foot Ulcers and Infections: A Health Economic Review

Chow, Ivy; Lemos, Elkin V.; Einarson, Thomas R. - In: PharmacoEconomics 26 (2008) 12, pp. 1019-1035

compared with prolonged antibacterials, MRI cost $US120 (year 1993 value) more without additional quality-adjusted life …

Persistent link: https://www.econbiz.de/10005404899

Economic Aspects of Pneumococcal Pneumonia: A Review of the Literature

De Graeve, Diana; Beutels, Philippe - In: PharmacoEconomics 22 (2004) 11, pp. 719-740

In this review, the economic aspects of pneumococcal pneumonia are analysed, including the costs, cost effectiveness and cost benefit of treatment and prevention. We identified eight cost-of-illness studies, 15 analyses comparing the costs of different treatment options and 15 economic...

Persistent link: https://www.econbiz.de/10005404998

Abciximab: A Pharmacoeconomic Review of its Use in Percutaneous Coronary Revascularisation

Dunn, Christopher J.; Foster, Rachel H. - In: PharmacoEconomics 16 (1999) 6, pp. 711-741

Abciximab is a monoclonal antibody fragment that inhibits platelet aggregation through antagonism of glycoprotein IIb/IIIa. The drug is used in conjunction with heparin and aspirin to prevent ischaemic complications associated with percutaneous coronary revascularisation in patients with...

Persistent link: https://www.econbiz.de/10005243110